NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, weigh in on the topic.
- Others, such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Daniel Lefler, MD, also contribute to the discussion.
No specific quotes are provided in the given text.
Additional experts, including Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, are mentioned as part of the discussion.
Author's summary: NGS improves biomarker testing for solid tumors.
More News
- Importing beef is not the solution | GABEL
- First Duel Night Abyss Figure Is Based on Psyche
- [Event] 15th Annual New York Forum on Economic Sanctions - December 3rd - 4th, New York, NY | JD Supra
- This "Biohacker" Tech Founder Claims to Have Cleaned the Microplastics from His Testes
- NDP fundraiser claims U.S. corporate money funding Yukon Party ‘attack ads’
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Colorado health insurance premiums to double, 75,000 may lose coverage
- Battlefield 6’s New Free-To-Play Battle Royale Mode Launches Tomorrow
- 400,000 Coloradans have cast votes so far
- SJHN Daily: Celebrini Named NHL First Star of the Week